Page 7 - Hikma - Oncology booklet

Dosage adjustments recommendations

Cardiac Discontinue Adricin in patients who with
Impairment signs or symptoms of cardiomyopathy

Hepatic Adricin,USP is contraindicated in patients
Impairment with severe hepatic impairment.

The dose of Adricin, USP should be
 Serum total
bilirubin conc. decreased .

Serum bilirubin concentration Adricin, USP Dose reduction

1.2 to 3 mg/dL 50%
3.1 to 5 mg/dL 75%
> 5 mg/dL Do not initiate and Discontinue Adricin, USP

Side effects

Alopecia, nausea 02 Cardiomyopathy
and vomiting. 01 and Arrhythmias

Extravasation and 04 03 Secondary

Tissue Necrosis Malignancies

Severe 05 06 Tumor Lysis
Myelosuppression Syndrome

Radiation Sensitization

and Radiation Recall 07

6